Very pleased to announce BEAM-201, a multiplex base edited allo CAR-T therapy for T-ALL. 4x simultaneous base edits (96-99% editing at all four targets), 85% CAR , and robust, dose dependent tumor control in vitro/in vivo. Fantastic achievement by the whole team @BeamTx.

an absolute shame. @harvard cutting PhD admissions "The Organismic and Evolutionary Biology department will shrink its class size by roughly 75 percent to three new Ph.D. students [...] Molecular and Cellular Biology will reduce its figure to four new students, and Chemistry and Chemical Biology will go down to four or five admits" thecrimson.com/article/2025/…

Incredible results with GD2 CART in neuroblastoma. Huge congratulations to the Bambino Gesu team nejm.org/doi/full/10.1056/NE…

Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines dlvr.it/SXvlVs

Congratulations to @JKeithJoung for winning the 2022 Ho-Am Prize in Medicine for his many contributions to advancing the field of genome editing! 👏🍻🎉 hoamfoundation.org/eng/award…

Today we report in @CellCellPress an engineered virus-like particle (eVLP) platform that mediates efficient in vivo delivery of therapeutic proteins, including base editors and Cas9 nuclease, resulting in therapeutic editing in multiple mouse organs. 1/14 drive.google.com/file/d/1GdJ…

We have completed our first experiments on neutralization of Omicron by Pfizer BNT162b2 vaccination elicited immunity Manuscript available at sigallab.net/ and should be available on medRxiv in the coming days

New base editing cell therapy data at SITC! Focusing here on CD5 CART (relevant for T cell lymphomas), we make 5 different edits simultaneously at 94% efficiency, without double strand breaks: globenewswire.com/news-relea…

Excited to report our latest progress in our 3Q filing! Most importantly, the BEAM-101 IND is now open, designated safe to proceed by the FDA. BEAM-102 IND-enabling studies are also underway. globenewswire.com/news-relea…

It’s a good time to remind everyone of the data from $BEAM: multiplex base editing does not alter T cell karyotype or growth (but multiplex Cas9 editing does)

A thread: Many talented scientists including Alexis Komor and @NicoleGaudelli worked tirelessly starting in 2013 to develop and apply cytosine and adenine base editors, systems that directly edit targeted DNA base pairs in living cells without cutting the DNA double helix./1

Our new paper on second infusions of CD19 CAR T-cells is finally out *in print* in @BloodJournal ! doi.org/10.1182/blood.202000… Time for a little Tweetorial 😄 Please retweet for your CAR T-cell friends/aficionados 😉 [THREAD 🧵] 1/24 @fredhutch @RyanCassaday

Congrats to @BeamTx and our own @Jason__Gehrke for creating our first allogenic CAR-T development candidate (Beam-201)! BEAM-201 is a potent and specific anti-CD7, multiplex base edited, allogeneic CAR-T development candidate for the treatment of T-ALL! globenewswire.com/news-relea…

What an unexpected/strange piece of T cell biology

And it's finally out! If you thought that CAR-Tregs would be just like CAR-T cells, think again. Great collaboration with @SangamoTx @JaDaFo Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells stm.sciencemag.org/content/1…